share_log

ABVC BioPharma, Inc. (OTCMKTS:ABVC) Forecasted to Post Q1 2023 Earnings of ($0.05) Per Share

ABVC BioPharma, Inc. (OTCMKTS:ABVC) Forecasted to Post Q1 2023 Earnings of ($0.05) Per Share

ABVC 生物製藥股份有限公司(OTCMK:ABVC)預計 2023 年第一季後的每股盈利為(0.05 美元)
Defense World ·  2023/01/20 02:21

ABVC BioPharma, Inc. (OTCMKTS:ABVC – Get Rating) – Zacks Small Cap issued their Q1 2023 earnings estimates for ABVC BioPharma in a research report issued on Wednesday, January 18th. Zacks Small Cap analyst M. Marin anticipates that the company will post earnings of ($0.05) per share for the quarter. The consensus estimate for ABVC BioPharma's current full-year earnings is ($0.56) per share. Zacks Small Cap also issued estimates for ABVC BioPharma's Q2 2023 earnings at ($0.06) EPS, Q3 2023 earnings at ($0.05) EPS and Q4 2023 earnings at ($0.04) EPS.

ABVC 生物製藥公司(OTCMKTS:ABVC-獲得評級)— 扎克斯小型股在 1 月 18 日(週三)發布的一份研究報告中發布了 ABVC 生物製藥的 2023 年第一季度收入估計。扎克斯小型股分析師馬林預計,該公司將公佈本季度每股收益(0.05 美元)。ABVC 生物製藥目前全年盈利的共識估計為每股 0.56 美元。扎克斯小型股還發布了 ABVC 生物製藥 2023 年第二季度盈利(0.06 美元),2023 年第三季盈利為每股盈利(0.05 美元)和 2023 年第四季盈利(0.04 美元)的估計值。

Get
取得
ABVC BioPharma
ABVC 生物製藥
alerts:
警報:

Separately, Maxim Group cut shares of ABVC BioPharma from a "buy" rating to a "hold" rating in a report on Wednesday, November 16th.

另外,美心集團在 11 月 16 日星期三的報告中削減 ABVC 生物製藥的股份從「買入」評級為「持有」評級。

ABVC BioPharma Price Performance

ABVC 生物製藥價格表現

ABVC opened at $0.78 on Thursday. The stock has a market capitalization of $25.46 million, a PE ratio of -1.15 and a beta of 0.50. The firm's fifty day moving average price is $0.75 and its 200 day moving average price is $0.80. ABVC BioPharma has a 12-month low of $0.50 and a 12-month high of $3.17.
ABVC 星期四以 0.78 美元開盤。該股的市值為 2546 萬美元,私募股票比率為 -1.15,測試版為 0.50。該公司的五十天移動平均價格為 0.75 美元,其 200 日移動平均價格為 0.80 美元。ABVC 生物製藥的價格為 12 個月低點 0.50 美元,為 12 個月高點 3.17 美元。

ABVC BioPharma (OTCMKTS:ABVC – Get Rating) last posted its quarterly earnings results on Monday, November 14th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.09. The company had revenue of $0.04 million during the quarter, compared to analyst estimates of $0.03 million.

ABVC 生物製藥(OTCMKTS:ABVC-獲取評級)上次公佈其季度業績於 11 月 14 日(星期一)。該公司報告了本季度的每股盈利(0.11 美元),超過了 0.09 美元的共識估計(0.20 美元)。該公司在本季度的營收為 0.04 萬美元,而分析師估計為 0.03 萬美元。

ABVC BioPharma Company Profile

ABVC 生物製藥公司簡介

(Get Rating)

(取得評分)

ABVC BioPharma, Inc, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage.

ABVC BioHharma, Inc. 是一家臨床階段生物製藥公司,致力於開發藥物和醫療設備,以滿足美國未滿足的醫療需求。公司正在開發 ABV-1501,目前正在進行 I/II 期臨床試驗,一種三陰性乳腺癌的聯合療法;ABV-1504 已完成重大抑鬱症的 II 期臨床試驗;ABV-1505 已完成治療胰腺癌的 I 期臨床試驗;已完成治療骨髓增生障礙的 I 期臨床試驗;ABV-1703 已完成治療胰腺癌的 I 期臨床試驗;治療癌症患者抑鬱症的臨床試驗;及 ABV-1702 ABV-1601ABV-1701 用於治療視網膜脫落或玻璃體出血的治療。

Further Reading

進一步閱讀

  • Get a free copy of the StockNews.com research report on ABVC BioPharma (ABVC)
  • Exxon Mobil Stock: Within Striking Distance Of Buy Point
  • High-Dividend-Yielding BHP Sees China Driving '23 Growth
  • Is Airbnb Setting Up To Rally 38%, As Analysts Are Forecasting?
  • Does a Price Cut for Tesla Vehicles Mean the Same for TSLA Stock?
  • Microsoft Layoffs Signal Layoffs for Other Tech Companies?
  • 獲取有關 ABVC 生物製藥研究報告的免費副本
  • 埃克森美孚股票:在買入點的醒目距離內
  • 高股息收益的必和必拓認為中國推動 23 年增長
  • Airbnb 是否正在設置上漲 38%,正如分析師的預測?
  • 特斯拉車輛的降價是否意味著 TSLA 股票相同?
  • 微軟裁員信號裁員為其他科技公司?

Receive News & Ratings for ABVC BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABVC BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.

每日接收 ABVC 生物製藥的新聞和評分 -在下面輸入您的電子郵件地址,以通過 MarketBeat.com 的免費每日電子郵件通訊接收 ABVC 生物製藥及相關公司的最新新聞和分析師評級的簡要每日摘要。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論